Purpose. The user flagged a rumor ("Merck and other pharma are finally getting good results from running quantum sims on actual molecular docking work, this has never happened before") and asked us to find the primary source before committing to a half-day-to-full-day deep dive. This is the 30-min verify pass that decides whether the deep-dive is warranted.

Verdict. The rumor doesn't validate as stated. Two separate quantum-healthcare workstreams have produced primary-source-grade results in April 2026, but neither is "Merck doing molecular docking." The real news is:

1. IBM Q4Bio Challenge winners (April 2026) — Algorithmiq + Cleveland Clinic + IBM, $2M prize. Photodynamic therapy + DM1 drug-protein binding on IBM Nighthawk 120-qubit hardware.
2. Merck KGaA + Amgen + Deloitte + QuEra Quantum Reservoir Computing (2025, published in J. Chem. Inf. Model.) — clinical trial outcome prediction with small datasets, NOT molecular docking.

The "Merck + molecular docking" framing conflates these. Full half-day-to-full-day deep dive is NOT warranted — there is no single primary source confirming the user's claim because the claim's shape is wrong. But the underlying quantum-healthcare news is real and worth a tighter integration update.

What the user heard vs. what actually happened

What actually happened — two distinct workstreams

Workstream 1: IBM Q4Bio Challenge — April 2026

• Sponsor: Wellcome Leap (nonprofit) — Quantum for Bio (Q4Bio) program
• Structure: $2M for "significant healthcare algorithm on 50+ qubits" (awarded); $5M grand prize for "real-world healthcare problem on 100+ qubits that cannot be solved classically" (NOT awarded — much prize money "may remain unawarded" per MIT Tech Review)
• Winner ($2M): Algorithmiq (startup) + Cleveland Clinic + IBM
• Application: Photodynamic therapy (PDT) — cancer treatment based on light-activated drugs. Molecular electronic structure simulations.
• Hardware: IBM Quantum Nighthawk processor with 120 qubits; circuits run on up to 100 qubits at 1,000-10,000 gate depth
• Other finalists named:
  • Infleqtion — cancer signature identification in genomic data
  • Oxford University team — genetic diversity mapping
  • Nottingham team — drug-protein binding for myotonic dystrophy type 1 (DM1)
• Big pharma involvement: None. Merck, Pfizer, Roche, AstraZeneca, GSK, Novartis, BMS, Amgen, Lilly all absent from the Q4Bio finalist list.
• Primary source: IBM Newsroom 2026-04-16 (blocked WebFetch on first attempt but content extracted via alternative path); IBM Quantum Blog
• Status: Research / proof-of-concept. Peer-reviewed publications listed as "may not yet be publicly available or indexed."

Workstream 2: Merck KGaA + QuEra Quantum Reservoir Computing — 2025

• Partners: Merck KGaA (German pharma; Xetra-listed MRK / OTC MKKGY) + Amgen + Deloitte + QuEra Computing
• Method: Quantum Reservoir Computing (QRC) — hybrid approach using quantum system to transform data before feeding it into classical ML
• Application: Clinical trial outcome prediction with small datasets (rare-disease trials specifically) — NOT molecular docking, NOT binding affinity
• Result: QRC embeddings "often matched or outperformed standard algorithms when training examples were scarce"
• Primary source: Published in Journal of Chemical Information and Modeling (per HPCwire writeup; full citation needs ACS search)
• Status: Peer-reviewed. Pre-commercial.

Why the rumor probably formed

The April 2026 IBM Q4Bio + March 2026 Quantinuum Singapore announcements created a wave of quantum-healthcare news. Add the older Merck KGaA + QuEra paper (which gets re-circulated in industry roundups), the @ChurchillWw / @Gaurab-class voices we don't usually see on this thesis, and a vendor-class messenger probably said "Merck + quantum + pharma" while the actual story is "Algorithmiq + Cleveland Clinic + IBM." The rumor compresses three things:

1. Real but separate Merck KGaA work (clinical-trial prediction, NOT docking)
2. Real Q4Bio Challenge results (not Merck, IS application-adjacent to docking via PDT and DM1 binding)
3. The general "quantum-for-pharma is real now" thematic from MIT Tech Review and other coverage

Per feedback_sources_are_discovery_surface_not_thesis.md, the rumor was a discovery surface that pointed us at a real signal, even though the rumor itself was wrongly-shaped. The real signal is the Q4Bio Challenge results + IBM Nighthawk 120-qubit milestone.

Updates to existing framing

Refines 2026-05-26-quantum-thesis-first-principles-validation.md

The first-principles investigation put commercial quantum advantage at 2028-2032. The Q4Bio data point refines this:

• Floor stays 2028. The $5M Q4Bio grand prize ("100+ qubits solving problems classically impossible") was NOT awarded in 2026 — the absence is the most informative datapoint. Wellcome Leap's program director publicly hedged on whether the grand prize will ever be awarded under near-term-NISQ assumptions.
• 120-qubit Nighthawk is the new SOTA baseline. Up from ~96 logical qubits in early-2026 framing. Useful as a benchmark for tracking quantum-platform progress quarter-over-quarter.
• Hybrid quantum-classical workflows are working at proof-of-concept scale. This is the dominant near-term paradigm — pure-quantum advantage on full molecular docking is still 2028+, but hybrid workflows that use ~100 qubits to transform classical pipelines are showing real (publishable) results NOW.
• PDT (photodynamic therapy) and DM1 are the two specific applications with publishable 2026 results. Worth tagging as "first non-toy targets that quantum addressed at the 100-qubit scale." Not commercial advantage, but the first real-disease proof-of-concept.

Trade-thesis implication on the quantum-pure-play cohort

What this closes vs. what stays open

Closes:

• The user-flagged "Merck molecular docking" rumor as stated. Reality: not Merck, not molecular docking exactly, but quantum-healthcare is real at proof-of-concept scale.
• Whether the half-day-to-full-day deep dive is warranted. No — the rumor's primary-source target doesn't exist in the shape claimed.

Stays open / new follow-ups filed:

• Track the next Q4Bio cycle — next round expected ~April 2027. Calendar catalyst: if any team clears the $5M grand prize bar (100+ qubits, classically impossible), that would shift the 2028-2032 framing forward.
• Get the actual J. Chem. Inf. Model. paper from Merck KGaA + QuEra — useful as a primary-source reference even though it's clinical-trial-prediction not docking. Filed below.
• INFQ / Infleqtion ticker disambiguation — RESOLVED 2026-05-27. INFQ IS Infleqtion (formerly ColdQuanta). NYSE-listed since Feb 2026 via Churchill Capital X SPAC. The first-principles validation note was correct; this verify note was wrong. Internal cross-note paraphrase-laundering corrected.
• Merck KGaA (MKKGY OTC / MRK Xetra) coverage decision — separate entity from MRK on NYSE. Worth a security-master row? Currently zero coverage of European Merck. Defer until any quantum thesis hardens enough to actually trade it.

Action items (filed below)

• Pull the actual Merck KGaA + Amgen + Deloitte + QuEra paper from Journal of Chemical Information and Modeling. ~15 min. Validates the QRC framing and gives a real citation.
• Verify INFQ-the-public-ticker is NOT Infleqtion (the Q4Bio finalist). Resolved 2026-05-27 via @thestockwhale tweet re-trigger: INFQ IS Infleqtion (NYSE, Feb 2026 SPAC). Corrections applied above.
• Calendar catalyst: 2027-04 (next Q4Bio cycle). Track: does the $5M grand prize get awarded? If yes, 2028-2032 framing shifts forward. If no, current framing roughly holds for another year.
• Update 2026-05-26-quantum-thesis-first-principles-validation.md with: (a) new SOTA baseline 120-qubit Nighthawk; (b) PDT + DM1 as the two first-disease-targets at the 100-qubit scale; (c) refined 2028-2032 framing noting the $5M Q4Bio prize is still unawarded.

Sources

• Price-truth waiver: this note verifies program facts and ticker identity, not the tape — the one market figure (INFQ ~$3.2B cap, as of 2026-05-22) is from contemporaneous listing coverage, dated in place, and is not a trade input.
• Quantum Case Study: Merck, Amgen, Deloitte, and QuEra Tackle Clinical Trial Prediction — HPCwire (2025-04-10) — primary source on the Merck KGaA QRC work; published in J. Chem. Inf. Model.
• IBM Details Q4Bio Outcomes — HPCwire (2026-04) — Q4Bio Challenge winners writeup
• IBM Quantum blog — Q4Bio Finalists (2026-04-16) — IBM-side primary source on Algorithmiq/Cleveland Clinic win + 120-qubit Nighthawk + 1,000-10,000 gate depth claim
• Can quantum computers now solve health care problems? — MIT Technology Review (2026-03-19) — Q4Bio program framing + $5M grand prize details + program director skepticism quote
• Quantum revolution in pharma — McKinsey — sector framing context